TherapeuticsMD Inc (NASDAQ:TXMD) – Equities research analysts at Oppenheimer increased their Q2 2019 EPS estimates for shares of TherapeuticsMD in a research note issued on Tuesday, June 11th. Oppenheimer analyst J. Olson now forecasts that the company will post earnings per share of ($0.14) for the quarter, up from their prior forecast of ($0.16). Oppenheimer currently has a “Outperform” rating and a $10.00 price target on the stock. Oppenheimer also issued estimates for TherapeuticsMD’s Q3 2019 earnings at ($0.16) EPS, Q4 2019 earnings at ($0.09) EPS, FY2019 earnings at ($0.55) EPS and FY2023 earnings at $1.20 EPS.
Several other research firms have also recently issued reports on TXMD. BidaskClub cut shares of TherapeuticsMD from a “sell” rating to a “strong sell” rating in a report on Tuesday, May 14th. ValuEngine cut shares of TherapeuticsMD from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Zacks Investment Research cut shares of TherapeuticsMD from a “hold” rating to a “sell” rating in a report on Thursday, February 28th. Noble Financial reaffirmed an “outperform” rating and issued a $13.00 price target on shares of TherapeuticsMD in a report on Tuesday, April 30th. Finally, Jefferies Financial Group cut their price target on shares of TherapeuticsMD from $5.00 to $4.00 and set a “hold” rating on the stock in a report on Tuesday, May 7th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $9.41.
TXMD opened at $2.58 on Friday. The firm has a market capitalization of $593.41 million, a P/E ratio of -4.37 and a beta of 2.14. The company has a debt-to-equity ratio of 1.26, a quick ratio of 3.28 and a current ratio of 3.39. TherapeuticsMD has a 12-month low of $2.21 and a 12-month high of $7.42.
TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings results on Monday, May 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.01. The firm had revenue of $3.95 million for the quarter, compared to analysts’ expectations of $5.96 million. TherapeuticsMD had a negative net margin of 907.71% and a negative return on equity of 159.71%. The firm’s quarterly revenue was up 4.8% on a year-over-year basis. During the same period in the prior year, the company posted ($0.11) earnings per share.
A number of institutional investors and hedge funds have recently bought and sold shares of TXMD. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of TherapeuticsMD by 26.1% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 17,648 shares of the company’s stock worth $67,000 after purchasing an additional 3,649 shares during the period. Rhumbline Advisers raised its holdings in shares of TherapeuticsMD by 51.5% during the fourth quarter. Rhumbline Advisers now owns 240,143 shares of the company’s stock worth $915,000 after purchasing an additional 81,646 shares during the period. Creative Planning acquired a new stake in shares of TherapeuticsMD during the fourth quarter worth $63,000. Public Employees Retirement Association of Colorado raised its holdings in shares of TherapeuticsMD by 24.8% during the fourth quarter. Public Employees Retirement Association of Colorado now owns 1,336,900 shares of the company’s stock worth $5,094,000 after purchasing an additional 265,400 shares during the period. Finally, California Public Employees Retirement System raised its holdings in shares of TherapeuticsMD by 515.5% during the fourth quarter. California Public Employees Retirement System now owns 200,000 shares of the company’s stock worth $762,000 after purchasing an additional 167,508 shares during the period. 78.93% of the stock is currently owned by hedge funds and other institutional investors.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.
Featured Story: How accurate is the Rule of 72?
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.